MMR inserts

SHULS are requiring people to have MMR in order to enter the facility. I imagine those doing so have not done their homework, to see why requiring it from everyone is a very severe misjudgment and overreach. We have done the homework for you, but feel free to check the links. Especially from the manufacturer themselves.
______________________

See how they give one thing to the doctor and another to you the patient
https://vaccines.procon.org/sourcefiles/MMRII_Package_Insert.pdf

In larger print, here is what is given to doctors
https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf

And here is what is for patients (who obviously can't understand the previous material 😷)
https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_ppi.pdf

Below all the reasons TO GIVE MMR have been removed. People know why they want to get vaccinated.
Here are reasons to NOT GIVE MMR from the PACKAGE INSERT GIVEN TO DOCTORS

Doctors are told

M-M-R II should be given one month before or after administration of other live viral vaccines

In other words, don't bunch together with other vaccines. Ever.

The rest of this is straight from what doctors are told. Commentary in between.

Infants Between 6 to 12 Months of Age Local health authorities may recommend measles vaccination of infants between 6 to 12 months of age in outbreak situations. This population may fail to respond to the components of the vaccine. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established. The younger the infant, the lower the likelihood of seroconversion (see CLINICAL PHARMACOLOGY). 

In other words, giving to babies = bad idea.

Unnecessary doses of a vaccine are best avoided by ensuring that written documentation of vaccination is preserved and a copy given to each vaccinee's parent or guardian. 

Over-vaccinating = bad idea

Other Vaccination Considerations
Vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which in turn prevents infection of the fetus and consequent congenital rubella injury.

This is fine. As we always say, those who want to vaccinate should vaccinate!

Women of childbearing age should be advised not to become pregnant for 3 months after vaccination and should be informed of the reasons for this precaution. 

Another way to say this: IF YOU ARE TRYING TO GET PREGNANT, DON'T GET THE MMR VACCINE

Postpubertal females should be informed of the frequent occurrence of generally self-limited arthralgia and/or arthritis beginning 2 to 4 weeks after vaccination (see ADVERSE REACTIONS).

In other words, if you are a woman you have a much higher chance of getting arthritis from the vaccine than a male has. So let the buyer beware. 

CONTRAINDICATIONS

Hypersensitivity to any component of the vaccine, including gelatin.{40} Do not give M-M-R II to pregnant females; the possible effects of the vaccine on fetal development are unknown at this time. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for three months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and PRECAUTIONS, Pregnancy). 

We don't know how the vaccine will impact the development of the fetus. Best to avoid possibly HARMING the child. Note again the indication to AVOID PREGNANCY FOR THREE MONTHS AFTER RECEIVING MMR

Who else should not get the shot? Those who have

• Anaphylactic or anaphylactoid reactions to neomycin (each dose of reconstituted vaccine contains approximately 25 mcg of neomycin). 4 
• Febrile respiratory illness or other active febrile infection. However, the ACIP has recommended that all vaccines can be administered to persons with minor illnesses such as diarrhea, mild upper respiratory infection with or without low-grade fever, or other low-grade febrile illness.{41} 
• Patients receiving immunosuppressive therapy. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease. 
• Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. 
• Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestations of infection with human immunodeficiency viruses;{41-43} cellular immune deficiencies; and hypogammaglobulinemic and dysgammaglobulinemic states. Measles inclusion body encephalitis{44} (MIBE), pneumonitis{45} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. 
• Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated. 

Most of these are auto-immune issues, which we think is accepted by everyone as a "medical exemption." Clearly there IS A RECOMMENDED MEDICAL EXEMPTION

What else are doctors told?

WARNINGS 

• Due caution should be employed in administration of M-M-R II to persons with a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided. The physician should be alert to the temperature elevation which may occur following vaccination (see ADVERSE REACTIONS). 
• Hypersensitivity to Eggs 
• Live measles vaccine and live mumps vaccine are produced in chick embryo cell culture. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving vaccines containing traces of chick embryo antigen. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases. Such individuals may be vaccinated with extreme caution, having adequate treatment on hand should a reaction occur (see PRECAUTIONS).

In other words, be sure to have a defibrillator on hand when administering the vaccine to someone with an egg allergy.

They go on to say that "Most children with a history of anaphylactic reactions to eggs have no untoward reactions to measles or MMR vaccine. Persons are not at increased risk if they have egg allergies that are not anaphylactic, and they should be vaccinated in the usual manner. In addition, skin testing of egg-allergic children with vaccine has not been predictive of which children will have an immediate hypersensitivity reaction...Persons with allergies to chickens or chicken feathers are not at increased risk of reaction to the vaccine."

We continue:

• Hypersensitivity to Neomycin 
• The AAP states, "Persons who have experienced anaphylactic reactions to topically or systemically administered neomycin should not receive measles vaccine. Most often, however, neomycin allergy manifests as a contact dermatitis, which is a delayed-type (cell-mediated) immune response rather than anaphylaxis. In such persons, an adverse reaction to neomycin in the vaccine would be an erythematous, pruritic nodule or papule, 48 to 96 hours after vaccination. A history of contact dermatitis to neomycin is not a contraindication to receiving measles vaccine."{47} 
• Thrombocytopenia 
• Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R II (or its component vaccines) may develop thrombocytopenia with repeat doses. Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases (see ADVERSE REACTIONS). 

PRECAUTIONS 

Vaccination should be deferred for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human).
Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. 

Though they backtrack this (next sentence), this does indicate that the recently vaccinated could infect others. 

There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk.{33} However, transmission of the rubella vaccine virus to infants via breast milk has been documented (see Nursing Mothers). 

Make up your mind, guys!

No studies have been reported to date of the effect of measles virus vaccines on untreated tuberculous children. However, individuals with active untreated tuberculosis should not be vaccinated. As for any vaccine, vaccination with M-M-R II may not result in protection in 100% of vaccinees. 

This indicates that some people who are vaccinated, are AS DANGEROUS AS THE UNVACCINATED!! AAAAHHHHHHHHHH

 Information for Patients The health-care provider should provide the vaccine information required to be given with each vaccination to the patient, parent, or guardian. The health-care provider should inform the patient, parent, or guardian of the benefits and risks associated with vaccination. 

How often does this happen? Never!!!

For risks associated with vaccination see WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS. Patients, parents, or guardians should be instructed to report any serious adverse reactions to their health-care provider who in turn should report such events to the U.S. Department of Health and Human Services through the Vaccine Adverse Event Reporting System (VAERS), 1-800-822-7967.

We were surprised at how many people are unaware of the existence of VAERS.

Pregnancy should be avoided for 3 months following vaccination, and patients should be informed of the reasons for this precaution (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females, CONTRAINDICATIONS, and PRECAUTIONS, Pregnancy). 

There's that warning about pregnancy again!!

Immune Globulin Administration of immune globulins concurrently with M-M-R II may interfere with the expected immune response.{33,34,47} 6 See also PRECAUTIONS, General.
Carcinogenesis, Mutagenesis, Impairment of Fertility M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility. 
Pregnancy Animal reproduction studies have not been conducted with M-M-R II. It is also not known whether M-M-R II can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, the vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see INDICATIONS AND USAGE, Non-Pregnant Adolescent and Adult Females and CONTRAINDICATIONS).

Fascinating. It is NOT KNOWN (because no studies have been done) as to what impact the MMR has on a woman's ability to conceive a child. Considering the huge infertility market today, one wonders how much vaccines have contributed to people's ability to get pregnant. And, we don't know if it helps cause cancer! "has not been evaluated for carcinogenic potential!!!!!!"

Nursing Mothers It is not known whether measles or mumps vaccine virus is secreted in human milk. Recent studies have shown that lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants.{53} In the infants with serological evidence of rubella infection, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.{54,55} Caution should be exercised when M-M-R II is administered to a nursing woman.

Here comes the instructions for babies under 12 months, and for people over the age of 65. In six words: We don't know if it's safe.

 Pediatric Use Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established (see also CLINICAL PHARMACOLOGY). Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established.
Geriatric Use Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. 

We continue

ADVERSE REACTIONS The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:
Body as a Whole Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.
Cardiovascular System Vasculitis.
Digestive System Pancreatitis; diarrhea; vomiting; parotitis; nausea.
Endocrine System Diabetes mellitus.
Hemic and Lymphatic System Thrombocytopenia (see WARNINGS, Thrombocytopenia); purpura; regional lymphadenopathy; leukocytosis.
Immune System Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history. 7
Musculoskeletal System Arthritis; arthralgia; myalgia.
Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children. This type of involvement as well as myalgia and paresthesia, have also been reported following administration of MERUVAX II.
Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms. Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%; women: 12-26%),{17,56,57} and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in women older than 35 years, these reactions are generally well tolerated and rarely interfere with normal activities.
Nervous System Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia. Encephalitis and encephalopathy have been reported approximately once for every 3 million doses of M-M-R II or measles-, mumps-, and rubella-containing vaccine administered since licensure of these vaccines. The risk of serious neurological disorders following live measles virus vaccine administration remains less than the risk of encephalitis and encephalopathy following infection with wild-type measles (1 per 1000 reported cases).

This last statistic is factually inaccurate. The 1 in a 1000 is from an outbreak in 1989 when the 1 in a 1000 who came to the hospital may have died. Most people didn't come to the hospital because they knew to just quarantine the child at home. Which means that the 1 in 1000 was of the WORST CASES, those who had other issues they were dealing with beyond regular wild measles.

Cases of aseptic meningitis have been reported to VAERS following measles, mumps, and rubella vaccination. Although a causal relationship between the Urabe strain of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl Lynn™ mumps vaccine to aseptic meningitis. 

Continuing...

Respiratory System Pneumonia; pneumonitis (see CONTRAINDICATIONS); sore throat; cough; rhinitis.
Skin Stevens-Johnson syndrome; erythema multiforme; urticaria; rash; measles-like rash; pruritis. Local reactions including burning/stinging at injection site; wheal and flare; redness (erythema); swelling; induration; tenderness; vesiculation at injection site; Henoch-Schönlein purpura; acute hemorrhagic edema of infancy.
Special Senses — Ear Nerve deafness; otitis media.
Special Senses — Eye Retinitis; optic neuritis; papillitis; retrobulbar neuritis; conjunctivitis. 8
Urogenital System Epididymitis; orchitis.
Other Death from various, and in some cases unknown, causes has been reported rarely following vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been established in healthy individuals (see CONTRAINDICATIONS). No deaths or permanent sequelae were reported in a published post-marketing surveillance study in Finland involving 1.5 million children and adults who were vaccinated with M-M-R II during 1982 to 1993.{61} Under the National Childhood Vaccine Injury Act of 1986, health-care providers and manufacturers are required to record and report certain suspected adverse events occurring within specific time periods after vaccination. However, the U.S. Department of Health and Human Services (DHHS) has established a Vaccine Adverse Event Reporting System (VAERS) which will accept all reports of suspected events.{49} A VAERS report form as well as information regarding reporting requirements can be obtained by calling VAERS 1-800-822-7967. 

It is NOT so simple. To suggest we are ill-informed, to suggest we haven't done our homework, to suggest that vaccines are SAFE for EVERYONE and EFFECTIVE for all, is simply not true, as indicated in the insert.